Katharine Collins

A documentary about the R21 malaria vaccine that I invented ~13 years ago while working in Oxford is airing tonight, 8pm BBC2! After I left Oxford ~10 years ago, many wonderful people continued to develop the vaccine, and as of last week the vaccine is now finally being rolled out in Africa! #TheBattleToBeatMalaria #R21 @DrMSDatoo @HalTinto @Fredros_Inc @ally_olotu @SerumInstIndia @JennerInstitute @Novavax bbc.co.uk/programmes/m00….

@JacobTref Woohoo! This is amazing! We’re so sad to lose you, but so excited about what you will achieve ❤️🎉

I'm joining the OpenAI Foundation to lead the Life Sciences & Curing Diseases program. We're starting with three areas of grantmaking: * AI for Alzheimer's * Public Data for Health * Accelerating Progress on High-Mortality and High-Burden Diseases Time to get to work!

.@coeff_giving directed over $1b in 2025, the most in our history. I wrote a more personal annual letter this year, focusing on what a decade of grantmaking has taught me, how I'm thinking about AI, and how we're grappling with giving at this scale. 🧵

Today we celebrate the international day of women and girls in science 🎉👩🏾‍🔬👩🏻‍💻👩🏾‍🚀👩🏼‍🔧 #IDWGS2026 (sketch by Sophia Hernandez)

ANNOUNCEMENT! The call for the 2026 edition of our Mentoring Program for #MothersInSTEMM is now open! Designed to empower women studying or working in #STEMM fields to achieve their career goals while juggling motherhood- without burnout. Apply now! mothersinscience.com/mentoring-prog…

The @WHO 2025 World malaria report brings a clear message: drug resistance threatens to undo hard-won gains against #malaria. With progress stalling, we must double down on innovation, surveillance and long-term commitment to stay ahead of resistance 👉 bit.ly/48JynVs

Some news: Open Philanthropy is now Coefficient Giving! Our mission is unchanged but the new name reflects our growing work with other donors to multiply the impact of their giving. 🧵 on our work to make philanthropy a more efficient "market" and plans going forward:

We’re looking for people who 1) are excited to grow with us 2) bring scientific understanding, analytical rigor, and strong judgment, 3) are curious about how global health innovations move from research to real-world impact. Apply by December 4: openphilanthropy.org/careers (5/5)

This is a chance to engage deeply with cutting-edge biomedical research while shaping neglected global health product development efforts. Our team directs over $100M each year toward high-impact science and innovation, and we plan to expand in 2026 (4/5)

📢 Come and work with me! 🌟 Open Philanthropy’s Science and Global Health R&D team is hiring a Program Officer and Senior Program Associates! (1/5)

Really cool jobs! Our science and global health R&D teams make a wide variety of grants focused on neglected and high mortality/morbidity diseases — a couple of recent examples in the images but lots more in our grants database. Apply to join us!

🚨 Hiring scientists to help give away money 🚨 At @open_phil, we have given away $600M in biomedical research since 2016. Now, we're expanding the team to do more. Hiring: * Up to 3 Senior Program Associates * Program Officer in strep A Remote OK, salaries in links! (thread)

LAUNCH DAY 🚀 Today I’m launching a new podcast, Hard Drugs, with Jacob Trefethen (@JacobTref) Our first episode is about lenacapavir — a new HIV drug that blocks infections with an efficacy rate of nearly 100%, and which could completely change the fight against HIV worldwide. It’s also about the scientific journey leading up to this point, and how HIV was transformed from a lethal to a manageable condition. 3:52 How was HIV discovered? Where did it come from, and how does it attack the body and cause AIDS? 38:10 Antiretrovirals: How did scientists develop breakthrough HIV drugs — from azidothymidine to protease inhibitors to PrEP? 1:51:35 How does prevention and treatment work today? 2:19:03 HIV’s capsid and the breakthrough of lenacapavir, the first-approved HIV capsid inhibitor 2:50:36 How to develop long-lasting treatments 3:14:45 Lenacapavir’s near 100% efficacy in clinical trials 3:48:40 The impact of global programs against HIV, and can we now end HIV?

📢 new publication from Alexandra Probst et al - an in vivo screen of 81 compounds against Plasmodium falciparum activity during the mosquito stage ⬇️

@albrgr @alexwcohen Yes, Open Phil is supporting the hut trials!

Pfs48/45 nanobodies block transmission 🦟 Pfs48/45 Nb-Fc reduce oocysts 💎 Structure of transmission-blocking Nb with Pfs48/45 👐🏽 Bispecific Nb-Fc targeting Pfs230 and Pfs48/45 🧑🏻‍🔬 PhD student Frankie Lyons 1st Author 🥳 Please repost & happy reading! biorxiv.org/content/10.110…

Alongside @kwambo_2, @Nghitalesheni, @tinasudi1 & @oumouthier, we came together to recognize the strength and resilience by communities affected by #malaria. We also shine a spotlight on a crucial force in the fight against malaria: #Women. #WorldMalariaDay #MalariaEndsWithUs

This World Malaria Day, we celebrate the vital role women & other discriminated genders play in the fight against malaria! From pioneering researchers to dedicated health workers, women are driving innovation & change in malaria control globally. [Sketch by Sophia & Thorey 👩🏻‍🎨]